AbbVie Inc. Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable
AbbVie Inc. (ABBV) reported Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable of -$2.30 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable · last filed 2026-08-03
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2026-06-30 was -$2.22B.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2026-03-31 was -$81.00M, a 121.43% decline year-over-year.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2025-12-31 was $646.00M.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2025-09-30 was -$411.00M, a 905.88% decline year-over-year.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2025 was -$762.00M.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2024 was -$3.21B.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2023 was -$488.00M, a 190.04% decline from fiscal 2022.
- AbbVie Inc. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2022 was $542.00M.
| Period end | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$2.30B 10-Q · filed 2026-08-03 | -$1.66B derived: sum of 3 quarters · filed 2026-08-03 | -$2.07B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$81.00M 10-Q · filed 2026-05-08 | $565.00M derived: sum of 2 quarters · filed 2026-05-08 | $154.00M derived: sum of 3 quarters · filed 2026-05-08 | -$1.22B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $646.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $235.00M derived: sum of 2 quarters · filed 2026-02-20 | -$1.14B derived: sum of 3 quarters · filed 2026-08-03 | -$762.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$411.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.79B derived: sum of 2 quarters · filed 2026-08-03 | -$1.41B 10-Q · filed 2025-11-04 | -$3.21B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$1.38B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$997.00M 10-Q · filed 2026-08-03 | -$2.80B derived: sum of 3 quarters · filed 2026-08-03 | -$2.75B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $378.00M 10-Q · filed 2026-05-08 | -$1.43B derived: sum of 2 quarters · filed 2026-05-08 | -$1.37B derived: sum of 3 quarters · filed 2026-05-08 | -$3.21B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.80B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$1.75B derived: sum of 2 quarters · filed 2026-02-20 | -$3.59B derived: sum of 3 quarters · filed 2026-02-20 | -$3.21B 10-K · filed 2026-02-20 |
| 2024-09-30 | $51.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.78B derived: sum of 2 quarters · filed 2025-11-04 | -$1.41B 10-Q · filed 2025-11-04 | -$994.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$1.83B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$1.46B 10-Q · filed 2025-08-04 | -$1.04B derived: sum of 3 quarters · filed 2026-02-20 | -$1.01B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $378.00M 10-Q · filed 2025-05-09 | $789.00M derived: sum of 2 quarters · filed 2026-02-20 | $822.00M derived: sum of 3 quarters · filed 2026-02-20 | -$297.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $411.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $444.00M derived: sum of 2 quarters · filed 2026-02-20 | -$675.00M derived: sum of 3 quarters · filed 2026-02-20 | -$488.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | $33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$1.09B derived: sum of 2 quarters · filed 2024-11-04 | -$899.00M 10-Q · filed 2024-11-04 | -$541.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$1.12B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$932.00M 10-Q · filed 2024-08-07 | -$574.00M derived: sum of 3 quarters · filed 2025-02-14 | -$280.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $187.00M 10-Q · filed 2024-05-03 | $545.00M derived: sum of 2 quarters · filed 2025-02-14 | $839.00M derived: sum of 3 quarters · filed 2025-02-14 | $291.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $358.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $652.00M derived: sum of 2 quarters · filed 2025-02-14 | $104.00M derived: sum of 3 quarters · filed 2025-02-14 | $542.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | $294.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$254.00M derived: sum of 2 quarters · filed 2023-11-06 | $184.00M 10-Q · filed 2023-11-06 | -$478.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$548.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$110.00M 10-Q · filed 2023-08-07 | -$772.00M derived: sum of 3 quarters · filed 2024-02-20 | -$838.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $438.00M 10-Q · filed 2023-05-05 | -$224.00M derived: sum of 2 quarters · filed 2024-02-20 | -$290.00M derived: sum of 3 quarters · filed 2024-02-20 | -$1.04B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$662.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$728.00M derived: sum of 2 quarters · filed 2024-02-20 | -$1.48B derived: sum of 3 quarters · filed 2024-02-20 | -$1.29B 10-K · filed 2024-02-20 |
| 2021-09-30 | -$66.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$819.00M derived: sum of 2 quarters · filed 2022-11-04 | -$628.00M 10-Q · filed 2022-11-04 | -$903.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | -$753.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$562.00M 10-Q · filed 2022-08-04 | -$837.00M derived: sum of 3 quarters · filed 2023-02-17 | -$1.34B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $191.00M 10-Q · filed 2022-05-06 | -$84.00M derived: sum of 2 quarters · filed 2023-02-17 | -$586.00M derived: sum of 3 quarters · filed 2023-02-17 | -$573.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | -$275.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$777.00M derived: sum of 2 quarters · filed 2023-02-17 | -$764.00M derived: sum of 3 quarters · filed 2023-02-17 | -$573.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | -$502.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$489.00M derived: sum of 2 quarters · filed 2021-11-02 | -$298.00M 10-Q · filed 2021-11-02 | -$589.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $204.00M 10-Q · filed 2021-08-02 | -$87.00M derived: sum of 3 quarters · filed 2022-02-18 | $6.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $191.00M 10-Q · filed 2021-05-07 | -$100.00M derived: sum of 2 quarters · filed 2022-02-18 | -$7.00M derived: sum of 3 quarters · filed 2022-02-18 | |
| 2019-12-31 | -$291.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$198.00M derived: sum of 2 quarters · filed 2022-02-18 | -$1.02B 10-K · filed 2022-02-18 | |
| 2019-09-30 | $93.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$727.00M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | -$820.00M 10-Q · filed 2020-08-04 | |||
| 2018-12-31 | $674.00M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |